| Literature DB >> 30350176 |
K Evert1, C Stiegler2, C Schäfer2, K Palme3, E Horndasch2, S Reitinger2, B M Rau4, W Dietmaier5, M Evert5.
Abstract
Adenosquamous carcinoma (ASqC) is an exceedingly rare subtype of colorectal cancer without any known special guidelines for treatment. The biological behaviour and molecular background are widely unknown, although a few case studies report a worse prognosis compared to ordinary colorectal adenocarcinoma. We herein report for the first time the successful immune checkpoint inhibitor therapy in a 40-year-old patient suffering from metastasized right-sided colonic ASqC with unique molecular features, after having previously progressed under standard chemotherapy.Entities:
Keywords: Adenosquamous colorectal carcinoma; FOLFOX4; Immune checkpoint inhibition; Microsatellite instability
Mesh:
Substances:
Year: 2019 PMID: 30350176 DOI: 10.1007/s00292-018-0546-3
Source DB: PubMed Journal: Pathologe ISSN: 0172-8113 Impact factor: 1.011